Digitizing CMC: opportunities and constraints for artificial intelligence adoption across CGT development and manufacturing

“...I expect AI to accelerate readiness for clinical and commercial operations by several years, alleviating longstanding bottlenecks across development and launch.”

Ashling Cannon (Commissioning Editor, Cell & Gene Therapy Insights) speaks with Kumar Dhanasekharan (SVP, Head of Technical Operations, Voyager Therapeutics Inc.) about the digitization barriers limiting artificial intelligence adoption in CMC and supply chain operations for cell and gene therapies, and the technical and regulatory considerations required to achieve real-time orchestration and operational resilience.

Please enter your email to access content Read now